3B BlackBio DX Reports Mixed Q2 Results: Revenue Up, EBITDA Margin Contracts

3B BlackBio DX , a leading player in the molecular diagnostics sector, has reported a mixed set of financial results for the second quarter. The company saw growth in revenue and marginal improvement in net profit, but experienced a decline in EBITDA and EBITDA margin.

Financial Highlights

Metric	Q2 FY2026	Q2 FY2025	YoY Change
Revenue	339.00	291.50	+16.3%
Net Profit	147.10	146.50	+0.4%
EBITDA	147.30	161.80	-9.0%
EBITDA Margin	43.45%	55.49%	-12.04 pp

All figures in million rupees, except percentages. pp = percentage points

Revenue Growth

3B BlackBio DX reported a consolidated revenue of 339.00 million rupees for the quarter, marking a significant increase of 16.3% compared to 291.50 million rupees in the same period last year. This growth in revenue indicates the company's ability to expand its market presence and increase sales despite challenging market conditions.

Profitability

The company's net profit showed marginal growth, increasing to 147.10 million rupees from 146.50 million rupees in the corresponding quarter of the previous year. This represents a modest year-over-year growth of 0.4%.

EBITDA and Margin Contraction

Despite the revenue growth, 3B BlackBio DX experienced a decline in its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). The EBITDA for Q2 FY2026 stood at 147.30 million rupees, down from 161.80 million rupees in Q2 FY2025, representing a 9% decrease.

More notably, the company's EBITDA margin contracted significantly, falling to 43.45% from 55.49% in the previous year. This 12.04 percentage point decrease in EBITDA margin suggests that the company faced increased costs or pricing pressures during the quarter.

Market Position and Future Outlook

According to the company's investor presentation, 3B BlackBio DX holds a 12%-15% market share in the Indian Molecular Diagnostics (MDx) sector, which has a total addressable market of approximately 350-450 crore rupees. The company aims to grow at 15%-20% for FY 2025-26, outpacing the projected industry growth rate of 8%-10% CAGR.

The company's growth strategy includes expanding its product portfolio, particularly in the areas of antimicrobial resistance (AMR) testing and next-generation sequencing (NGS) assays. 3B BlackBio DX has also completed the acquisition of Coris BioConcept SRL, a Belgium-based manufacturer of rapid diagnostic test kits, which is expected to complement its existing molecular diagnostics product range.

While the company faces challenges in terms of margin pressure, its focus on innovation, market expansion, and strategic acquisitions may position it for future growth in the competitive molecular diagnostics market.

Investors and analysts will likely be watching closely to see how 3B BlackBio DX addresses the margin contraction while continuing to drive revenue growth in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.92%	+0.81%	-3.72%	-23.20%	-16.37%	+51.06%

3B BlackBio Dx Limited , a leading player in India's molecular diagnostics market, has reported strong financial results for the first quarter of fiscal year 2026, along with a strategic international acquisition.

Q1 FY26 Financial Highlights

The company reported sales of ₹19.96 crores for Q1 FY26, representing an impressive 18% year-on-year increase from ₹16.94 crores in the same quarter last year. EBITDA grew by 11% to reach ₹16.19 crores.

Strategic Acquisition

In a significant move to expand its global footprint, 3B BlackBio Dx has acquired Coris Bioconcept, a Belgium-based rapid diagnostics company, for up to £4.77 million. This acquisition is expected to strengthen the company's presence in the European market and broaden its product portfolio.

Market Position and Growth Outlook

3B BlackBio Dx currently holds a 12-15% market share in India's molecular diagnostics market. The company is projecting a growth rate of 15-20% for FY26, outpacing the industry's expected growth of 8-10%.

Business Segment Performance

Segment	Projected Growth
Domestic	15-20%
Export	20-25%

The company aims to increase its export contribution from the current 17-18% to 35-40% of total revenue within the next five years.

Profitability and Capacity Utilization

EBITDA margins for the core business are approximately 60%, although the company expects these to trend towards 55% due to increasing competition. Current capacity utilization stands at 65%, with no major capital expenditure required for the next 2-3 years.

Future Outlook

With its strong market position, strategic acquisition, and focus on both domestic and export growth, 3B BlackBio Dx is well-positioned to capitalize on the expanding molecular diagnostics market. The company's emphasis on research and development, coupled with its efficient capital utilization, suggests a promising outlook for sustained growth and profitability.

Investors and industry observers will be keen to watch how the integration of Coris Bioconcept progresses and how it contributes to 3B BlackBio Dx's international expansion strategy in the coming quarters.